Brimonidine: A new alpha2-adrenoreceptor agonist for glaucoma treatment

David Greenfield, Jeffrey M. Liebmann, Robert Ritch

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Purpose: Brimonidine is a highly selective alpha2-adrenoceptor agonist. It has intraocular pressure (IOP)-lowering characteristics similar to other alpha2-agonists and acts by reducing aqueous humor production and increasing uveoscleral outflow. It is oxidatively stable, which may account for its lower reported rate of ocular allergy compared with other alpha2-agonists. The focus of this report is to review the receptor pharmacology and clinical experience with brimonidine tartrate, the newest of the alpha2-adrenergic agonists. Methods: Clinical studies have been performed for acute indications using the 0.5% concentration and chronic indications using the 0.2% concentration. Results: Brimonidine 0.5% given as one drop before, after, or both before and after 360°argon laser trabeculoplasty significantly lowers the incidence of postlaser IOP spikes. Brimonidine 0.28 instilled twice daily offers long-term IOP control comparable with that achieved with timolol 0.5% and better than betatolol 0.25% suspension. Conclusions: In light of these data, brimonidine 0.5% may be considered for prophylaxis against laser-induced IOP spikes and brimonidine 0.2% for chronic use in patients with ocular hypertension and glaucoma.

Original languageEnglish
Pages (from-to)250-258
Number of pages9
JournalJournal of Glaucoma
Volume6
Issue number4
StatePublished - Aug 1 1997
Externally publishedYes

Fingerprint

Glaucoma
Intraocular Pressure
Lasers
Therapeutics
Adrenergic alpha-2 Receptor Agonists
Timolol
Ocular Hypertension
Trabeculectomy
Aqueous Humor
Clinical Pharmacology
Adrenergic Receptors
Brimonidine Tartrate
Suspensions
Hypersensitivity
Incidence

Keywords

  • Alpha2-adrenoreceptor agonist
  • Brimonidine

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Brimonidine : A new alpha2-adrenoreceptor agonist for glaucoma treatment. / Greenfield, David; Liebmann, Jeffrey M.; Ritch, Robert.

In: Journal of Glaucoma, Vol. 6, No. 4, 01.08.1997, p. 250-258.

Research output: Contribution to journalArticle

Greenfield, David ; Liebmann, Jeffrey M. ; Ritch, Robert. / Brimonidine : A new alpha2-adrenoreceptor agonist for glaucoma treatment. In: Journal of Glaucoma. 1997 ; Vol. 6, No. 4. pp. 250-258.
@article{d4e1218908574d9aa770f78ee77fda12,
title = "Brimonidine: A new alpha2-adrenoreceptor agonist for glaucoma treatment",
abstract = "Purpose: Brimonidine is a highly selective alpha2-adrenoceptor agonist. It has intraocular pressure (IOP)-lowering characteristics similar to other alpha2-agonists and acts by reducing aqueous humor production and increasing uveoscleral outflow. It is oxidatively stable, which may account for its lower reported rate of ocular allergy compared with other alpha2-agonists. The focus of this report is to review the receptor pharmacology and clinical experience with brimonidine tartrate, the newest of the alpha2-adrenergic agonists. Methods: Clinical studies have been performed for acute indications using the 0.5{\%} concentration and chronic indications using the 0.2{\%} concentration. Results: Brimonidine 0.5{\%} given as one drop before, after, or both before and after 360°argon laser trabeculoplasty significantly lowers the incidence of postlaser IOP spikes. Brimonidine 0.28 instilled twice daily offers long-term IOP control comparable with that achieved with timolol 0.5{\%} and better than betatolol 0.25{\%} suspension. Conclusions: In light of these data, brimonidine 0.5{\%} may be considered for prophylaxis against laser-induced IOP spikes and brimonidine 0.2{\%} for chronic use in patients with ocular hypertension and glaucoma.",
keywords = "Alpha2-adrenoreceptor agonist, Brimonidine",
author = "David Greenfield and Liebmann, {Jeffrey M.} and Robert Ritch",
year = "1997",
month = "8",
day = "1",
language = "English",
volume = "6",
pages = "250--258",
journal = "Journal of Glaucoma",
issn = "1057-0829",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Brimonidine

T2 - A new alpha2-adrenoreceptor agonist for glaucoma treatment

AU - Greenfield, David

AU - Liebmann, Jeffrey M.

AU - Ritch, Robert

PY - 1997/8/1

Y1 - 1997/8/1

N2 - Purpose: Brimonidine is a highly selective alpha2-adrenoceptor agonist. It has intraocular pressure (IOP)-lowering characteristics similar to other alpha2-agonists and acts by reducing aqueous humor production and increasing uveoscleral outflow. It is oxidatively stable, which may account for its lower reported rate of ocular allergy compared with other alpha2-agonists. The focus of this report is to review the receptor pharmacology and clinical experience with brimonidine tartrate, the newest of the alpha2-adrenergic agonists. Methods: Clinical studies have been performed for acute indications using the 0.5% concentration and chronic indications using the 0.2% concentration. Results: Brimonidine 0.5% given as one drop before, after, or both before and after 360°argon laser trabeculoplasty significantly lowers the incidence of postlaser IOP spikes. Brimonidine 0.28 instilled twice daily offers long-term IOP control comparable with that achieved with timolol 0.5% and better than betatolol 0.25% suspension. Conclusions: In light of these data, brimonidine 0.5% may be considered for prophylaxis against laser-induced IOP spikes and brimonidine 0.2% for chronic use in patients with ocular hypertension and glaucoma.

AB - Purpose: Brimonidine is a highly selective alpha2-adrenoceptor agonist. It has intraocular pressure (IOP)-lowering characteristics similar to other alpha2-agonists and acts by reducing aqueous humor production and increasing uveoscleral outflow. It is oxidatively stable, which may account for its lower reported rate of ocular allergy compared with other alpha2-agonists. The focus of this report is to review the receptor pharmacology and clinical experience with brimonidine tartrate, the newest of the alpha2-adrenergic agonists. Methods: Clinical studies have been performed for acute indications using the 0.5% concentration and chronic indications using the 0.2% concentration. Results: Brimonidine 0.5% given as one drop before, after, or both before and after 360°argon laser trabeculoplasty significantly lowers the incidence of postlaser IOP spikes. Brimonidine 0.28 instilled twice daily offers long-term IOP control comparable with that achieved with timolol 0.5% and better than betatolol 0.25% suspension. Conclusions: In light of these data, brimonidine 0.5% may be considered for prophylaxis against laser-induced IOP spikes and brimonidine 0.2% for chronic use in patients with ocular hypertension and glaucoma.

KW - Alpha2-adrenoreceptor agonist

KW - Brimonidine

UR - http://www.scopus.com/inward/record.url?scp=0030611851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030611851&partnerID=8YFLogxK

M3 - Article

C2 - 9264305

AN - SCOPUS:0030611851

VL - 6

SP - 250

EP - 258

JO - Journal of Glaucoma

JF - Journal of Glaucoma

SN - 1057-0829

IS - 4

ER -